Fraxiparine Market

Nadroparin belongs to the class of medications known as anticoagulants or antithrombotic agents. These medications reduce the clotting ability of the blood and can reduce the risk of harmful blood clots forming in blood vessels. Nadroparin is used to prevent and treat deep vein thrombosis (DVT). This condition leads to the formation of blood clots in the blood vessels in the leg. These blood clots can sometimes travel to the lungs and block blood vessels there, resulting in a serious condition known as pulmonary embolism.

Fraxiparine Market contains market size and forecasts of Fraxiparine in global, including the following market information:

Global Fraxiparine Market Revenue, 2017-2022, 2023-2028, ($ millions)

Global Fraxiparine Market Sales, 2017-2022, 2023-2028, (MT)

Global top five Fraxiparine companies in 2021 (%)

The global Fraxiparine market was valued at million in 2021 and is projected to reach US$ million by 2028, at a CAGR of % during the forecast period.

The U.S. Market is Estimated at $ Million in 2021, While China is Forecast to Reach $ Million by 2028.

Anticoagulant Segment to Reach $ Million by 2028, with a % CAGR in next six years.

The global key manufacturers of Fraxiparine include Eisai Inc, Mitsubishi Tanabe Pharma Corporation, Aspen Holdings, Pfizer, Inc, Teva Pharmaceutical Industries Ltd, Bristol-Myers Squibb Company, Sanofi S.A, GlaxoSmithKline Plc and Bayer Healthcare AG, etc. In 2021, the global top five players have a share approximately % in terms of revenue.

We surveyed the Fraxiparine manufacturers, suppliers, distributors and industry experts on this industry, involving the sales, revenue, demand, price change, product type, recent development and plan, industry trends, drivers, challenges, obstacles, and potential risks.

Total Market by Segment:

Global Fraxiparine Market, by Type, 2017-2022, 2023-2028 ($ Millions) & (MT)

Global Fraxiparine Market Segment Percentages, by Type, 2021 (%)

Anticoagulant

Antithrombotic

Global Fraxiparine Market, by Application, 2017-2022, 2023-2028 ($ Millions) & (MT)

Global Fraxiparine Market Segment Percentages, by Application, 2021 (%)

General Surgery

Orthopaedic Surgery

Others

Global Fraxiparine Market, By Region and Country, 2017-2022, 2023-2028 ($ Millions) & (MT)

Global Fraxiparine Market Segment Percentages, By Region and Country, 2021 (%)

North America

US

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Nordic Countries

Benelux

Rest of Europe

Asia

China

Japan

South Korea

Southeast Asia

India

Rest of Asia

South America

Brazil

Argentina

Rest of South America

Middle East & Africa

Turkey

Israel

Saudi Arabia

UAE

Rest of Middle East & Africa

Competitor Analysis

The report also provides analysis of leading market participants including:

Key companies Fraxiparine revenues in global market, 2017-2022 (Estimated), ($ millions)

Key companies Fraxiparine revenues share in global market, 2021 (%)

Key companies Fraxiparine sales in global market, 2017-2022 (Estimated), (MT)

Key companies Fraxiparine sales share in global market, 2021 (%)

Further, the report presents profiles of competitors in the market, key players include:

Eisai Inc

Mitsubishi Tanabe Pharma Corporation

Aspen Holdings

Pfizer, Inc

Teva Pharmaceutical Industries Ltd

Bristol-Myers Squibb Company

Sanofi S.A

GlaxoSmithKline Plc

Bayer Healthcare AG

Boehringer Ingelheim

Abbott